Abstract 99P
Background
Combining immune checkpoint blockade (ICB) with chemotherapy may significantly improve efficacy in patients with breast cancer. Whether metronomic chemotherapy is more suitable for ICB than conventional chemotherapy is still unclear.
Methods
This study is a multicenter randomized phase 2 trial using a multi-arm design with Bayesian adaptive randomization and efficacy monitoring. Eligible patients have advanced HER2-negative breast cancer, with no more than one prior line of standard chemotherapy. Patients were randomized to 5 groups: 1) metronomic vinorelbine (NVB, 40 mg/day, TIW) monotherapy (the control cohort); 2) NVB + toripalimab (anti-PD1 antibody, 240 mg Q3W); 3) bevacizumab (5 mg/kg Q3W) + NVB+ toripalimab (the BEV cohort); 4) cisplatin (50mg/m Q3W) + NVB + toripalimab (the DDP cohort); 5) cyclophosphamide (50mg/day, QD) + capecitabine (500 mg, TID) + NVB+ toripalimab (the VEX cohort). The primary endpoint was disease control rate (DCR). Mass cytometry time-of-flight analyses of paired blood samples were performed to demonstrate dynamic changes in systemic immune profile.
Results
A total of 103 patients were randomized. The rate of nausea was significantly higher in the cisplatin cohort than in the others (P< 0.001). Among the five treatment cohorts, the VEX cohort and the cisplatin cohort had the highest DCR, 69.7% (95% CI 51.7–85.9%) and 73.7% (95% CI 56.1–88.7%), respectively. It is worth noting that the PFS of patients in the VEX cohort was the longest, reaching 6.6 months (95% CI 4.0-5.9). The PFS of patients in the DDP cohort was relatively short, only 3.5 months (95% CI 2.2-5.3). In the TNBC subgroup, again, patients in the VEX cohort had the highest DCR (74.1%, 95%CI 47.9%-95.4%) and longest PFS (9.8 months, 95%CI 3.8-21.9). We clustered CD45+ immune cells into 32 clusters. Only the change of cluster 30 differed between responders and non-responders. This is a group of intermediate monocytes with a high expression of CD38. Meanwhile, the overall expression of CD38 in monocytes was significantly increased by DDP and BEV treatment compared with baseline, but not in the VEX groups.
Conclusions
These data suggest promising clinical efficacy and evidence of cooperativity between metronomic VEX chemotherapy and PD-1 blockade.
Clinical trial identification
NCT04389073.
Legal entity responsible for the study
The authors.
Funding
CAMS Innovation Fund for Medical Sciences (CIFMS 2022-I2M-C&T-B-067).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
157TiP - Krascendo-170 Lung: a phase Ib/II study of divarasib + pembrolizumab _ platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)
Presenter: Ferdinandos Skoulidis
Session: Poster Display
159TiP - Two Phase 1 Studies Assessing the Safety and Efficacy of the Small Molecule Oral PD-L1 Inhibitor INCB099280 in Combination with Adagrasib (INCB 99280-204 [Study 204]) or Ipilimumab (INCB 99280-205 [Study 205]) in Adults with Advanced Solid Tumors
Presenter: David Berz
Session: Poster Display
160TiP - Safety and Antitumor Activity of GEN1042 in Combination with Pembrolizumab _ Chemotherapy in Solid Tumors: Phase 2b Dose-Expansion Trial in Progress
Presenter: Ignacio Melero
Session: Poster Display
164P - Disentangling the Joint and Distinct Immunomodulation and Vulnerability Between KEAP1/NFE2L2 and SMARCA4 Alterations in Lung Adenocarcinoma
Presenter: Anlin Li
Session: Poster Display
165P - Immunosuppressive F13A1+ Mo/M_ in the tumor microenvironment as a hallmark for multiple primary lung cancers
Presenter: Jiahao Qu
Session: Poster Display
166P - Three-dimensional (3D) Innervation of Mouse Lungs and Airways in a Lung Metastatic Tumor Model
Presenter: Yan Zhou
Session: Poster Display
167P - Lurbinectedin, a DNA minor groove inhibitor launches a multimodal immune response through activation of the cytosolic DNA-Sensing cGAS-STING pathway.
Presenter: Triparna Sen
Session: Poster Display
168P - Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC
Presenter: CATERINA DE ROSA
Session: Poster Display
169P - High-dimensional analysis of tumor infiltrating immune cells reveals major differences in the tumor immune microenvironments of pleural mesothelioma and lung cancer
Presenter: Angelica Rigutto
Session: Poster Display